3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neoplasm Metastasis
4
Neoplasms
3
Melanoma
3
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia
1
Insulin-Like Growth Factor I, Resistance To
1
Humoral Hypercalcemia Of Malignancy
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
Dexamethasone
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
tislelizumab
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
pembrolizumab
1
lortalamine
1
gossypol acetic acid
1
daratumumab
1
aflibercept
1
Prednisone
1
Oncolytic Virotherapy
1
Octreotide
1
Mitomycin
1
Mammography
1
Lenalidomide
1
Ipilimumab
1
Drug Delivery Systems
1
Docetaxel
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
Bevacizumab
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Disease
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled